Table 1.
Demographics and clinical characteristics of ‘combined’ cohort (N = 235).
| Characteristic | Number (percentage or range) |
|---|---|
| Median age in years at diagnosis (range) | 57 (35–80) |
| Number female (%) | 32 (13.6%) |
| HPV status: | |
| Overall HPV positive | 116 (49%) |
| Method of HPV status determination‘: | |
| HPV RNA positive (RNA seq) | 42 |
| HPV DNA (ISH) positive | 64 |
| p16 immunohistochemistry (IHC) | 10 |
| Negative | 98 (46%) |
| Unknown | 11 (5%) |
| Subsite: | |
| Base of tongue | 39 (16.5%) |
| Oropharynx* | 142 (60.5%) |
| Tonsil | 54 (23%) |
| Clinical Stage AJCC 7: | |
| I | 10 (4.2%) |
| II | 23 (9.7%) |
| III | 33 (13.9%) |
| IV | 18 (7.6%) |
| IVa | 134 (57%) |
| IVb | 13 (5.5%) |
| IVc | 4 (1.7%) |
| Clinical Stage AJCC 8: | |
| I | 71 (30%) |
| II | 40 (17%) |
| III | 44 (19%) |
| IV | 9 (4%) |
| IVa | 51 (21.8%) |
| IVb | 4 (2%) |
| IVc | 1 (0.2%) |
| NA | 15 (6%) |
| Number with more than 10 pack year history (%) | 186 (81%) |
| Median pack years of smokers (IQR) | 30 (12–60) |
| Number of patients receiving radiotherapy (%) | 177 (75%) |
| Number of patients receiving surgery (%) | 57 (24%) |
| Number of patients receiving chemotherapy (%) | 110 (47%) |
| Median follow up (years) | 2.34 |
| Number of events (overall survival) | 83 |
| Number of events (recurrence free survival) | 99 |
AJCC = American Joint Committee on Cancer.
‘Method of determination as described by authors of original paper. For details of overlap between different methods, if performed, please see Supplementary Table A4.
*Several series – specifically Walter and Wichmann consisted of 100% ‘oropharynx’ cases with no further definition of subsite (Supplementary Table A1).